Rexgenero rebrands as Ixaka, raises £40M following gene therapy deal

With an aim to bring its recently acquired synthetic gene delivery platform into the clinic, Rexgenero Ltd. has recapitalized and rebranded as cell and gene therapy company Ixaka Ltd.

The London-based biotech said undisclosed existing investors contributed £40 million ($54.1 million) in new capital, which CEO Joe Dupere described as an “early stage financing.” The company had raised about $14.2 million in a 2016 series A round...